Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Year: 2023
Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., June 05, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (NKGen), a clinical-stage…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) — Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company…
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001
– Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis…
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Carina Biotech (Carina), a cell therapy immuno-oncology…
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two…
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two…
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company)…
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the…
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the…
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
WALTHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…